Patent application number | Description | Published |
20090260753 | Method for Production of an Optical Mirror - In order to produce heliostats, which are used in solar-thermal power stations, the method according to the invention provides for a mirror plate ( | 10-22-2009 |
20100000570 | WASHING APPARATUS AND WASHING METHOD FOR SOLAR PANELS - Disclosed is a method for cleaning solar panels by means of a washing apparatus ( | 01-07-2010 |
20100071683 | Fresnel solar collector arrangement - The invention relates to a Fresnel solar collector arrangement consisting essentially of a receiver ( | 03-25-2010 |
20110180059 | SOLAR THERMAL ENERGY SYSTEM - In order to increase the efficiency of a solar thermal system, it is proposed that a measuring robot movable in the longitudinal extension, which can measure the radiance distribution directed at the receiver tube along the receiver and therefore can check if the reflectors of the system are correctly adjusted, be placed on the cover of the receiver, which is supported in a raised manner. | 07-28-2011 |
20130239948 | LINEARLY CONCENTRATING SOLAR COLLECTOR AND METHOD FOR REFLECTOR TRACKING IN SUCH A SOLAR COLLECTOR - The basis for the function of a linearly concentrating solar collector lies, in simple terms, in the fact that reflectors reflect incident sunlight onto a receiver tube through which a heat-absorbing medium flows. Owing to the rotation of the Earth, the reflectors need to be adjusted regularly, however, in order to ensure that the sunlight hits the receiver tube. Known tracking methods use calculated positions of the sun for this purpose, which, in the case of structural deviations, for example as a result of expansion and material stress, results in inaccuracies and losses in efficiency. The invention is intended to improve the tracking of the reflectors in such a linearly concentrating solar collector. This is achieved by virtue of the fact that the radiation intensity in the region on both sides next to the receiver tube is measured and, by means of regulation, in the case of uneven emission on both sides of the receiver tube, the reflectors are tracked to such an extent that the radiation intensity on both sides of the receiver is the same and thus the maximum of the radiation intensity is on the receiver tube. | 09-19-2013 |
Patent application number | Description | Published |
20090175893 | Albumin-Fused Anti-Angiogenesis Peptides - The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinopathy, progressive macular degeneration or rheumatoid arthritis. | 07-09-2009 |
20120263747 | Albumin-Fused Anti-Angiogenesis Peptides - The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis. | 10-18-2012 |
20140017273 | Albumin-Fused Anti-Angiogenesis Peptides - The present disclosure relates to albumin fusion protein including an angiogenesis inhibiting peptide, or a fragment or variant thereof, and albumin, or a fragment or variant thereof. The fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The disclosure includes therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits, as well as nucleic acid molecules encoding the albumin fusion proteins, vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins using these nucleic acids, vectors, and/or host cells. The disclosure further relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion. The disclosure further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis. | 01-16-2014 |